On 10 June 2026, Consun Pharmaceutical Group Limited executed an on-market repurchase of 67,000 ordinary shares, spending HK$0.93 million at prices ranging from HK$13.71 to HK$13.97 per share. The volume-weighted average price stood at HK$13.85.

\n\nFollowing the transaction, issued shares outstanding (excluding treasury stock) fell from 840.39 million to 840.32 million, a marginal 0.008% reduction. Treasury shares increased to 1.23 million, while the company’s total issued share count remained unchanged at 841.55 million.

\n\nThe buyback forms part of the mandate approved on 26 May 2026, which authorises repurchases of up to 84.12 million shares. To date, Consun Pharma has repurchased 0.89 million shares under this mandate, utilising around 1.05% of the authorised limit. In line with Hong Kong Stock Exchange requirements, the company is subject to a moratorium on new share issues or treasury-share sales until 10 July 2026.